专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011126327A3 PHARMACEUTICAL COMPOSITION WITH CONTROLLED-RELEASE PROPERTIES COMPRISING MOSAPRIDE OR LEVODROPROPIZINE, AND PREPARING METHOD THEREOF 审中-公开
标题翻译：具有包含MOSAPRIDE或LEVODROPROPROPIZINE的控制释放特性的药物组合物及其制备方法
公开(公告)号：WO2011126327A3
公开(公告)日：2012-02-02
申请号：PCT/KR2011002458
申请日：2011-04-07
申请人： HYUNDAI PHARM CO LTD , JEON HO-SEONG , SHIN YONG-KWAN , KO DAE-WOONG , IM SU-BIN , KIM KANG-MIN , RHEE JAE-KEOL , KAM SUNG-HOON
发明人： JEON HO-SEONG , SHIN YONG-KWAN , KO DAE-WOONG , IM SU-BIN , KIM KANG-MIN , RHEE JAE-KEOL , KAM SUNG-HOON
IPC分类号： A61K9/22 , A61K9/20 , A61K9/24 , A61K9/48 , A61K31/4418 , A61K31/5375 , A61K47/36 , A61K47/38
CPC分类号： A61K31/4418 , A61K9/205 , A61K9/209 , A61K31/5375
摘要： Disclosed is a sustained-release pharmaceutical composition comprising mosapride or levodropropizine as an active ingredient, a method of preparing the same, and a pharmaceutical composition with dual release property comprising a sustained-release part and an immediate release part respectively comprising the active ingredient. The sustained-release pharmaceutical composition may constantly release drugs despite change in internal organ movement state of a subject, and it may constantly release the active ingredient even if a long time passes after administration, and thus, it may sufficiently deliver drugs only with single dose or two doses per day. And, since the pharmaceutical composition with dual release property has an immediate part and a sustained-release part exhibiting independent release properties, it may simultaneously increase rapid pharmaceutical effect and convenience for internal use, and improved treatment effect may also be expected due to improved the dissolution stability.
摘要翻译：公开了包含莫沙必利或左旋丙嗪作为活性成分的缓释药物组合物，其制备方法和具有双重释放特性的药物组合物，其包含分别包含活性成分的缓释部分和速释部分。持续释放的药物组合物可以随着受试者的内部器官运动状态的变化而不断地释放药物，并且即使施用后长时间通过也可以不断地释放活性成分，因此，它可以仅用单一剂量充分输送药物或每天两剂。并且，由于具有双重释放特性的药物组合物具有立即的部分和具有独立释放性质的缓释部分，因此可以同时提高快速的药物效果和内部使用的便利性，并且由于改善了治疗效果溶解稳定性。

2. 发明申请

WO2012124982A3 ORAL PREPARATION HAVING AN ENTERIC COATING 审中-公开
标题翻译：口腔涂层的口腔准备
公开(公告)号：WO2012124982A3
公开(公告)日：2012-11-08
申请号：PCT/KR2012001846
申请日：2012-03-14
申请人： HYUNDAI PHARM CO LTD , RHEE JAE-KEOL , JEON HO-SEONG , KIM JIN-MO
发明人： RHEE JAE-KEOL , JEON HO-SEONG , KIM JIN-MO
IPC分类号： A61K9/28 , A61K9/16 , A61K9/48 , A61K31/675
CPC分类号： A61K9/48 , A61K9/16 , A61K9/28 , A61K31/675
摘要： The present invention relates to an oral preparation containing zoledronic acid, which reduces enteric injuries and improves bioavailability. More particularly, the present invention relates to an oral preparation having an enteric coating, which comprises zoledronic acid and the pharmaceutically acceptable salts thereof, and which has a core, the pH level of which is 3.5 to 7.
摘要翻译：本发明涉及含有唑来膦酸的口服制剂，其可减少肠损伤并提高生物利用度。更具体地，本发明涉及具有肠溶衣的口服制剂，其包含唑来膦酸及其药学上可接受的盐，并且其核苷酸的pH值为3.5至7。

3. 发明申请

WO2011149206A2 PHARMACEUTICAL COMPOSITION CONTAINING CRYSTALLINE NEBIVOLOL HYDROCHLORIDE AND METHOD FOR PREPARING THE SAME 审中-公开
标题翻译：含有晶体奈韦罗醇氢氯化物的药物组合物及其制备方法
公开(公告)号：WO2011149206A2
公开(公告)日：2011-12-01
申请号：PCT/KR2011003514
申请日：2011-05-12
申请人： HYUNDAI PHARM CO LTD , BIO PHARMARTIS CO LTD , CHAE JI-MAN , KAM SUNG-HOON , RHEE JAE-KEOL
发明人： CHAE JI-MAN , KAM SUNG-HOON , RHEE JAE-KEOL
IPC分类号： A61K31/352 , A61K9/22 , A61K31/718 , A61P9/00
CPC分类号： A61K9/2059 , A61K31/353
摘要： Disclosed is a pharmaceutical composition containing crystalline nebivolol hydrochloride and a method for preparing the same that enhances the dissolution rate of the crystalline nebivolol hydrochloride and minimizes the variance of dissolution rate to greatly enhance a desired therapeutic effect. The pharmaceutical composition includes: an active ingredient including an effective amount of crystalline nebivolol hydrochloride; and a pharmaceutically acceptable additive including starch, the pharmaceutical composition containing the crystalline nebivolol hydrochloride and the starch at a weight ratio of 1:15 to 1:40.
摘要翻译：公开了含有结晶奈必洛尔盐酸盐的药物组合物及其制备方法，其提高盐酸奈必洛因结晶的溶解速度，并使溶出速度的变化最小化，从而大大提高了所需的治疗效果。药物组合物包括：活性成分，其包含有效量的结晶盐酸奈必洛尔; 和包含淀粉的药学上可接受的添加剂，所述药物组合物以1:15至1:40的重量比含有结晶奈必洛尔盐酸盐和淀粉。

4. 发明申请

WO2011074791A3 PHARMACEUTICAL COMPOSITION CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE 审中-公开
标题翻译：含TELMISARTAN和HYDROCHLORLOTHIZZIDE的药物组合物
公开(公告)号：WO2011074791A3
公开(公告)日：2011-11-03
申请号：PCT/KR2010008204
申请日：2010-11-19
申请人： HYUNDAI PHARM CO LTD , RHEE JAE-KEOL , KAM SUNG-HOON , CHAE JI-MAN
发明人： RHEE JAE-KEOL , KAM SUNG-HOON , CHAE JI-MAN
IPC分类号： A61K9/20 , A61K9/24 , A61K31/4184 , A61K31/4422
CPC分类号： A61K45/06 , A61K9/2009 , A61K9/209 , A61K9/284
摘要： The present invention relates to a pharmaceutical composition containing telmisartan and hydrochlorothiazide, and particularly, the present invention relates to a pharmaceutical composition containing telmisartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a diuretic). The pharmaceutical composition of the present invention, having a compound containing polyvinylpyrrolidone (an inactive water soluble polymer) primarily coated on a telmisartan core, and a compound of hydrochlorothiazide (a diuretic) and polyvinylpyrrolidone secondarily coated thereon, can have a good diuretic dissolution rate, and is significantly smaller and lighter than commercial drugs of the prior art, so that administering dosages to patients can be easier, and the composition can be effectively used in the medical industry.
摘要翻译：含有替米沙坦和氢氯噻嗪的药物组合物本发明涉及含有替米沙坦和氢氯噻嗪的药物组合物，具体地说，本发明涉及含有替米沙坦（血管紧张素II受体拮抗剂）和氢氯噻嗪（利尿剂）的药物组合物。具有主要包被在替米沙坦芯上的包含聚乙烯吡咯烷酮（非活性水溶性聚合物）和二次包覆在其上的氢氯噻嗪（利尿剂）和聚乙烯吡咯烷酮的化合物的化合物的本发明的药物组合物可以具有良好的利尿剂溶解速率，并且与现有技术的商业药物相比明显更小和更轻，使得给患者施用剂量可以更容易，并且该组合物可以有效地用于医疗行业。

5. 发明申请

WO2010035985A2 METHOD FOR PRODUCING TAXANE DERIVATIVES 审中-公开
标题翻译：生产紫杉烷衍生物的方法
公开(公告)号：WO2010035985A2
公开(公告)日：2010-04-01
申请号：PCT/KR2009005279
申请日：2009-09-17
申请人： DONG A PHARM CO LTD , KIM MOON-SUNG , YOO MOO-HI , RHEE JAE-KEOL , KIM YONG-JIK , CHOI JUN-HO , SUNG SI-YOUNG , LIM HONG-GYU , CHA DAE-WON , SON BYOUNG-HWA , RYU KI-MOON
发明人： KIM MOON-SUNG , YOO MOO-HI , RHEE JAE-KEOL , KIM YONG-JIK , CHOI JUN-HO , SUNG SI-YOUNG , LIM HONG-GYU , CHA DAE-WON , SON BYOUNG-HWA , RYU KI-MOON
IPC分类号： C07D305/14
CPC分类号： C07D305/14
摘要： The present invention relates to a method for producing taxane derivatives with anticancer activity. The method of the present invention produces taxane derivatives in a short time under mild conditions by employing phenyl oxazinan dione compounds which are novel compounds, as a reactant, such that the phenyl oxazinan dione compounds react to baccatin III derivatives.
摘要翻译：本发明涉及生产具有抗癌活性的紫杉烷衍生物的方法。本发明的方法通过使用作为新化合物的苯基恶嗪烷二酮化合物作为反应物，在温和条件下在短时间内产生紫杉烷衍生物，使得苯基恶嗪烷二酮化合物与浆果赤霉素III衍生物反应。

6. 发明申请

WO2009084827A3 SYNTHETIC INTERMEDIATES, PROCESS FOR PREPARING PYRROLYLHEPTANOIC ACID DERIVATIVES THEREFROM 审中-公开
标题翻译：合成中间体，制备吡咯烷酮酸衍生物的方法
公开(公告)号：WO2009084827A3
公开(公告)日：2009-08-27
申请号：PCT/KR2008007350
申请日：2008-12-12
申请人： DONG A PHARM CO LTD , KIM MOON-SUNG , YOO MOO-HI , RHEE JAE-KEOL , KIM YONG-JIK , PARK SEONG-JIN , CHOI JUN-HO , SUNG SI-YOUNG , LIM HONG-GYU , CHA DAE-WON
发明人： KIM MOON-SUNG , YOO MOO-HI , RHEE JAE-KEOL , KIM YONG-JIK , PARK SEONG-JIN , CHOI JUN-HO , SUNG SI-YOUNG , LIM HONG-GYU , CHA DAE-WON
IPC分类号： C07D207/34 , A61P3/06
CPC分类号： C07D207/416
摘要： There are provided intermediates used to prepare a derivative, (3R,5R)-7-[2-(4-fluorphenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-lH-pyrrol-l-yl]-3,5-di hydroxyheptanoic acid, which has an effect to suppress cholesterol in blood, and a process for preparing pyrrolylheptanoic acid derivatives therefrom. In accordance with the present invention, the 5-(4-fluorphenyl)-2-isopropyl-4-phenyl-lH-pyrrole-3-carbonyl derivative is provided as one of the novel synthetic intermediates that are used to prepare pyrrolylheptanoic acid derivatives including a derivative, (3R,5R)-7-[2-(4-fluorphenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-lH-pyrrol-l-yl]-3,5-di hydroxyheptanoic acid. Therefore, the (3R,5R)-7-[2-(4-fluorphenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-lH-pyrrol-l-yl]-3,5-di hydroxyheptanoic acid derivative may be prepared from the carbonyl derivative in a high yield for a short time period under a moderate condition.
摘要翻译：提供用于制备衍生物的中间体（3R，5R）-7- [2-（4-氟苯基）-5-异丙基-3-苯基-4-（苯基氨基甲酰基）-1H-吡咯-1-基] - 具有抑制血液中胆固醇的作用的3,5-二羟基庚酸及其制备吡咯并庚酸衍生物的方法。根据本发明，提供5-（4-氟苯基）-2-异丙基-4-苯基-1H-吡咯-3-羰基衍生物作为用于制备吡咯基庚酸衍生物的新型合成中间体之一，包括衍生物（3R，5R）-7- [2-（4-氟苯基）-5-异丙基-3-苯基-4-（苯基氨基甲酰基）-1H-吡咯-1-基] -3,5-二羟基庚酸。因此，（3R，5R）-7- [2-（4-氟苯基）-5-异丙基-3-苯基-4-（苯基氨基甲酰基）-1H-吡咯-1-基] -3,5-二羟基庚酸衍生物可以在中等条件下以高产率从羰基衍生物制备短时间段。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式